


Product Name : Ceritinib
Cat. No. : PC-21774
CAS No. : 1032900-25-6
Molecular Formula : C₂₈H₃₆ClN₅O₃S
Molecular Weight : 558.14
Target : Anaplastic Lymphoma Kinase (ALK)
Solubility : 10 mM in DMSO



Biological Activity

Ceritinib (LDK378) is a potent, selective and orally active anaplastic lymphoma kinase (ALK) inhibitor with enzymatic IC₅₀ of 200 pM, overcomes crizotinib resistance in NSCLC.

Ceritinib (LDK378) shows high selectivity against an enzyme panel of 30 kinases, with 80-, 70-, and 230-fold for IGF-1R, InsR, and STK22D.

Ceritinib (LDK378) effectively inhibits ALK harboring L1196M, G1269A, I1171T, and S1206Y mutations, does not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C.

Ceritinib (LDK378) overcomes crizotinib resistance in non-small cell lung cancer.

References

Marsilje TH, et al. J Med Chem. 2013 Jul 25;56(14):5675-90.

Friboulet L, et al. Cancer Discov. 2014 Jun;4(6):662-673.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com